Matthew C. Sams

Array ( [id] => 20678152 [patent_doc_number] => 20260116964 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-04-30 [patent_title] => SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 19/065656 [patent_app_country] => US [patent_app_date] => 2025-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32825 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19065656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19170939 [patent_doc_number] => 20240156913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => TREATMENT AND PREVENTION OF METABOLIC DISEASES [patent_app_type] => utility [patent_app_number] => 18/482399 [patent_app_country] => US [patent_app_date] => 2023-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54255 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18482399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19157715 [patent_doc_number] => 20240150422 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => IL-12 FC FUSION PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/353729 [patent_app_country] => US [patent_app_date] => 2023-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60928 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18353729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18860281 [patent_doc_number] => 20230414715 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => TRAIL COMPOUNDS FOR REDUCING CANCER TREAMENT SIDE EFFECTS [patent_app_type] => utility [patent_app_number] => 18/327193 [patent_app_country] => US [patent_app_date] => 2023-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10393 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18327193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19586414 [patent_doc_number] => 20240383971 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => Anti-DFS70 Autoantibodies and methods of attenuating formation of nets [patent_app_type] => utility [patent_app_number] => 18/199248 [patent_app_country] => US [patent_app_date] => 2023-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5375 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18199248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18737985 [patent_doc_number] => 20230346888 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => METHOD AND COMPOSITION OF TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 18/140535 [patent_app_country] => US [patent_app_date] => 2023-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4846 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18140535 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18596033 [patent_doc_number] => 20230270824 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => INTERFERON-BASED CANCER TREATMENT METHOD AND PHARMACEUTICAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/099664 [patent_app_country] => US [patent_app_date] => 2023-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15336 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18099664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18692614 [patent_doc_number] => 20230322929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy [patent_app_type] => utility [patent_app_number] => 18/297983 [patent_app_country] => US [patent_app_date] => 2023-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22155 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18297983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18691010 [patent_doc_number] => 20230321195 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => EXOSOME ENCODED IL-10 AS A TREATMENT FOR INFLAMMATION ASSOCIATED ADVERSE PREGNANCY CONDITION [patent_app_type] => utility [patent_app_number] => 18/296755 [patent_app_country] => US [patent_app_date] => 2023-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9234 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18296755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19360882 [patent_doc_number] => 20240262916 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE [patent_app_type] => utility [patent_app_number] => 18/561127 [patent_app_country] => US [patent_app_date] => 2022-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28841 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -168 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18561127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19020235 [patent_doc_number] => 20240076406 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => SINGLE DOMAIN ANTIBODIES TARGETING CA-IX AS WELL AS COMPOSITIONS COMPRISING SAME [patent_app_type] => utility [patent_app_number] => 18/262392 [patent_app_country] => US [patent_app_date] => 2022-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21380 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18262392 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067253 [patent_doc_number] => 20240101679 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => STABLE AQUEOUS BUFFER FREE FORMULATION OF AN INTEGRIN ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/265812 [patent_app_country] => US [patent_app_date] => 2021-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5482 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18265812 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18987796 [patent_doc_number] => 20240059765 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES [patent_app_type] => utility [patent_app_number] => 18/265380 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28296 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18265380 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879165 [patent_doc_number] => 20240002534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => ARGINASE 1 BINDERS FOR INHIBITING ARGINASE 1 ACTIVITY [patent_app_type] => utility [patent_app_number] => 18/253702 [patent_app_country] => US [patent_app_date] => 2021-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20151 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18253702 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18862315 [patent_doc_number] => 20230416751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => MATERIALS AND METHODS FOR TREATING CORNEAL DYSFUNCTION [patent_app_type] => utility [patent_app_number] => 18/036494 [patent_app_country] => US [patent_app_date] => 2021-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12447 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18036494 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18829661 [patent_doc_number] => 20230398185 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => IL-2/IL-15R-BETA-GAMMA AGONIST FOR TREATING NON-MELANOMA SKIN CANCER [patent_app_type] => utility [patent_app_number] => 18/033524 [patent_app_country] => US [patent_app_date] => 2021-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29211 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18033524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19217831 [patent_doc_number] => 20240182535 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR MUTANTS [patent_app_type] => utility [patent_app_number] => 18/033252 [patent_app_country] => US [patent_app_date] => 2021-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12526 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -69 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18033252 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18844532 [patent_doc_number] => 20230406936 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => ANTI-PD-L1 ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/247252 [patent_app_country] => US [patent_app_date] => 2021-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15169 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18247252 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18675097 [patent_doc_number] => 20230312673 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => CHIMERIC RECEPTORS WITH DIVERSE CO-REGULATORY SEQUENCES [patent_app_type] => utility [patent_app_number] => 18/043716 [patent_app_country] => US [patent_app_date] => 2021-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35400 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043716 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18987798 [patent_doc_number] => 20240059767 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => TREATMENT OF DRY EYE SYNDROME USING AN OPHTHALMIC COMPOSITION COMPRISING TANFANERCEPT [patent_app_type] => utility [patent_app_number] => 18/261368 [patent_app_country] => US [patent_app_date] => 2021-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12455 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18261368 [rel_patent_id] =>[rel_patent_doc_number] =>)